JP2021501766A5 - - Google Patents

Download PDF

Info

Publication number
JP2021501766A5
JP2021501766A5 JP2020524501A JP2020524501A JP2021501766A5 JP 2021501766 A5 JP2021501766 A5 JP 2021501766A5 JP 2020524501 A JP2020524501 A JP 2020524501A JP 2020524501 A JP2020524501 A JP 2020524501A JP 2021501766 A5 JP2021501766 A5 JP 2021501766A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
crystal
composition according
composition
mutation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2020524501A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021501766A (ja
JP7335877B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2018/058930 external-priority patent/WO2019090059A1/en
Publication of JP2021501766A publication Critical patent/JP2021501766A/ja
Publication of JP2021501766A5 publication Critical patent/JP2021501766A5/ja
Priority to JP2023070786A priority Critical patent/JP7499377B2/ja
Application granted granted Critical
Publication of JP7335877B2 publication Critical patent/JP7335877B2/ja
Priority to JP2024090124A priority patent/JP7780576B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2020524501A 2017-11-02 2018-11-02 共結晶、その医薬組成物、およびそれを伴う治療方法 Active JP7335877B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2023070786A JP7499377B2 (ja) 2017-11-02 2023-04-24 共結晶、その医薬組成物、およびそれを伴う治療方法
JP2024090124A JP7780576B2 (ja) 2017-11-02 2024-06-03 共結晶、その医薬組成物、およびそれを伴う治療方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762580501P 2017-11-02 2017-11-02
US62/580,501 2017-11-02
PCT/US2018/058930 WO2019090059A1 (en) 2017-11-02 2018-11-02 Cocrystals, pharmaceutical compositions thereof, and methods of treatment involving same

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023070786A Division JP7499377B2 (ja) 2017-11-02 2023-04-24 共結晶、その医薬組成物、およびそれを伴う治療方法

Publications (3)

Publication Number Publication Date
JP2021501766A JP2021501766A (ja) 2021-01-21
JP2021501766A5 true JP2021501766A5 (https=) 2021-12-16
JP7335877B2 JP7335877B2 (ja) 2023-08-30

Family

ID=64572453

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2020524501A Active JP7335877B2 (ja) 2017-11-02 2018-11-02 共結晶、その医薬組成物、およびそれを伴う治療方法
JP2023070786A Active JP7499377B2 (ja) 2017-11-02 2023-04-24 共結晶、その医薬組成物、およびそれを伴う治療方法
JP2024090124A Active JP7780576B2 (ja) 2017-11-02 2024-06-03 共結晶、その医薬組成物、およびそれを伴う治療方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2023070786A Active JP7499377B2 (ja) 2017-11-02 2023-04-24 共結晶、その医薬組成物、およびそれを伴う治療方法
JP2024090124A Active JP7780576B2 (ja) 2017-11-02 2024-06-03 共結晶、その医薬組成物、およびそれを伴う治療方法

Country Status (16)

Country Link
US (3) US11345677B2 (https=)
EP (1) EP3704101A1 (https=)
JP (3) JP7335877B2 (https=)
KR (2) KR20240166601A (https=)
CN (2) CN111527076B (https=)
AU (2) AU2018360827B2 (https=)
CA (1) CA3081535A1 (https=)
EA (1) EA202091112A1 (https=)
IL (2) IL305426B2 (https=)
MA (1) MA50526A (https=)
MX (2) MX2020004513A (https=)
PH (1) PH12020550462A1 (https=)
SG (1) SG11202003612VA (https=)
TW (2) TWI839131B (https=)
UA (1) UA127380C2 (https=)
WO (1) WO2019090059A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20200085832A1 (en) * 2019-11-22 2020-03-19 Agios Pharmaceuticals, Inc. Deuterated analogs of an organic compound
AR123228A1 (es) 2020-08-12 2022-11-09 Servier Pharmaceuticals Llc Formas en estado sólido de un compuesto orgánico
WO2023192565A1 (en) 2022-03-31 2023-10-05 Servier Pharmaceuticals Llc Methods of treating enhancing brain tumors using combination therapy
AR133332A1 (es) 2023-07-25 2025-09-17 Servier Lab Sales, cocristales, composiciones farmacéuticas de los mismos, y métodos de tratamiento que implican los mismos
WO2025060940A1 (zh) * 2023-09-18 2025-03-27 贝达药业股份有限公司 突变型idh抑制剂化合物及其盐的固体形式
EP4538262A1 (en) 2023-10-12 2025-04-16 Sandoz Ag Cocrystals of vorasidenib
WO2025168757A1 (en) 2024-02-09 2025-08-14 Les Laboratoires Servier Process for the preparation of vorasidenib

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX382354B (es) * 2010-11-01 2025-03-13 Celgene Car Llc Compuestos heterocíclicos y usos de los mismos.
US9579324B2 (en) 2013-07-11 2017-02-28 Agios Pharmaceuticals, Inc Therapeutically active compounds and their methods of use
WO2015003360A2 (en) * 2013-07-11 2015-01-15 Agios Pharmaceuticals, Inc. Therapeutically active compounds and their methods of use

Similar Documents

Publication Publication Date Title
JP2021501766A5 (https=)
CN112912077B (zh) 用于治疗三阴性乳腺癌的组合疗法
TWI798199B (zh) 癌症治療
JP2019517487A5 (https=)
JP2023022190A (ja) 癌治療
CN109937041B (zh) 一种ezh2抑制剂与btk抑制剂联合在制备治疗肿瘤的药物中的用途
TWI594986B (zh) Antineoplastic agent effect enhancer
JP2015512942A5 (https=)
JP2021524835A5 (https=)
IL274123B2 (en) Cocrystals, pharmaceutical compositions thereof, and methods of treatment involving same
JP2019501185A (ja) 食道癌を治療するためのキノリン誘導体の使用とその治療方法、医薬組成物及びキット
US20220213014A1 (en) Crystalline polymorphs of 1,6-dibromo-1,6-dideoxy-dulcitol
CN102812010A (zh) 喹唑啉衍生物及其制备方法和应用
JP7441214B2 (ja) 前立腺がんの治療のための併用療法
JPWO2022132652A5 (https=)
JPWO2019195753A5 (https=)
TWI848990B (zh) 治療化療難治性癌症的新聯合用藥方案
US20190083499A1 (en) Chlorobenzene substituted azaaryl compounds
JP2024505252A (ja) Pten不活性化突然変異を有する患者における癌の治療
CN119569704A (zh) Ptk抑制剂a的异构体及应用
EP4593962A1 (en) Tetrahydroquinoline compounds as antitumor agents
EA051616B1 (ru) Лечение рака
HK40124738A (zh) 治疗化疗难治性癌症的新联合用药方案
Stein et al. What Chemotherapy to Recommend in Metastatic Patients?
TW202241846A (zh) 具有ep拮抗活性之化合物的鹽、溶劑合物及結晶